Regeneron Pharma (REGN) PT Raised to $895 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $812.74 +0.63%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Join SI Premium – FREE
Piper Sandler analyst Christopher Raymond raised the price target on Regeneron Pharma (NASDAQ: REGN) to $895.00 (from $885.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Regeneron extends BARDA Ebola treatment supply deal for $270M
- TMX Group (X:CN) (TMXXF) PT Raised to Cdn$67 at TD Securities
- Doman Building Materials Group Ltd (DBM:CN) (CWXZF) PT Lowered to Cdn$12.50 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
